Archive · 1 Dec 2025
Ozempic 2.0: Needle-Free Weight Loss Pill
Imagine a pill that can help you lose weight without needing injections.
That's what Ozempic 2.0, called Orforglipron, is all about.
Made by big drug companies Novo Nordisk and Eli Lilly, this pill is designed to help people with diabetes and obesity.
Early tests show it can help people lose more weight than the current Ozempic treatment.
The best part?
You just take it once a day, no needles needed!
But like any medicine, it might cause some side effects like feeling sick to your stomach or having an upset tummy.
The companies are working hard to get it approved so it can help lots of people soon.
Ozempic 2.0, named Orforglipron, is a once-daily pill for weight loss and diabetes treatment.
Manufactured by Novo Nordisk and Eli Lilly, it outperformed Ozempic in early trials with 9.2% average weight loss.
The pill offers a convenient, needle-free alternative to current injectable treatments.
Side effects include nausea, diarrhea, vomiting, and indigestion, similar to existing GLP-1 treatments.
Regulatory submissions are planned by year-end, with an expected global launch in 2026.
- Who
- Novo Nordisk and Eli Lilly
- What
- A new once-daily pill for weight loss and diabetes treatment
- When
- Regulatory submission planned by year-end, launch expected in 2026
- Where
- Global
- Why
- To provide a convenient, needle-free alternative to current injectable treatments
- Drug Name
- Orforglipron
- Manufacturers
- Novo Nordisk and Eli Lilly
- Average Weight Loss
- 9.2%
- Comparison to Ozempic
- Outperformed Ozempic with 9.2% vs. 5.3% weight loss
- Potential Side Effects
- Nausea, diarrhea, vomiting, indigestion
- Regulatory Submission
- Planned by year-end
- Expected Launch
- 2026
